| 摘要 |
<p>This invention provides use of a following compound (in particular venlafaxine) to prepare a medicament for treating obesity, post-traumatic stress disorder, late luteal phase disphoric disorder (premenstrual syndrome), attention deficit disorder, with and without hyperactivity, Gilles de la Tourette syndrome, bulimia nervosa or Shy Drager Syndrome. The compound is a hydroxycycloalkanephenethyl amine of the following structural formula:
<Chemistry id="chema01" num="0001"><Image id="ia01" he="41" wi="47" file="IMGA0001.TIF" imgContent="chem" imgFormat="TIFF" /></Chemistry>
in which A is a moiety of the formula
<Chemistry id="chema02" num="0002"><Image id="ia02" he="26" wi="29" file="IMGA0002.TIF" imgContent="chem" imgFormat="TIFF" /></Chemistry>
where
the dotted line represents optional unsaturation;
R<Sub>1</Sub> is hydrogen or alkyl;
R<Sub>2</Sub> is alkyl;
R<Sub>4</Sub> is hydrogen, alkyl, formyl, or alkanoyl;
R<Sub>5</Sub> and R<Sub>6</Sub> are, independently, hydrogen, hydroxyl, alkyl, alkoxy, alkanoyloxy, cyano, nitro, alkylmercapto, amino, alkylamino, dialkylamino, alkanamido, halo, trifluoromethyl, or taken together, methylene dioxy;
R<Sub>7</Sub> is hydrogen or alkyl; and
n is 0, 1, 2, 3, or 4;
or a pharmaceutically acceptable salt thereof.</p> |
